Files size/type shown when available.
A practical, capture-style breakdown of fit, requirements, risks, and next steps.
The THRIVE program under ARPA-H is focused on the treatment of hereditary rare diseases using in vivo precision genetic medicines. It seeks innovative solutions through research and development and aims to leverage advanced genetic technologies for effective therapeutic strategies. This initiative represents a unique funding opportunity for organizations specializing in genetic medicine, biotechnology, and rare diseases.
The buyer is aiming to solicit proposals that develop precision genetic medicines targeting hereditary rare diseases. The objective is to advance scientific understanding and applications of genetic therapies that can transform patient outcomes.
It summarizes awarded-contract behavior for the opportunity’s NAICS and sector, including a recent pricing band (P10–P90), momentum, and composition. Use it as context, not a guarantee.
The signal updates as new awarded notices enter the system. Always validate the official award and solicitation details on SAM.gov.
P10 is the 10th percentile award size and P90 is the 90th percentile. Together they describe the typical spread of award values.
